SF 433 (LSB 1440XS (4) 91)

SENATE FILE 433

BY  WAHLS

A BILL FOR

An Act relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

    Section 1.  DIRECT ACTING ANTIVIRAL MEDICATION —— MEDICAID PRIOR AUTHORIZATION.  Notwithstanding section 249A.20A, subsection 4, the department of health and human services shall not require prior authorization for any direct acting antiviral medications used to treat hepatitis C that are on the preferred drug list.
    Sec. 2.  IOWA MEDICAL ASSISTANCE DRUG UTILIZATION REVIEW COMMISSION —— VOSEVI REVIEW.  The Iowa medical assistance drug utilization review commission created under section 249A.24 shall, by July 1, 2026, review the prescription drug vosevi for placement on the preferred drug formulary pursuant to 42 U.S.C. §1396r-8 as a preferred direct acting antiviral for treatment of hepatitis C.
EXPLANATION
The inclusion of this explanation does not constitute agreement with
the explanation’s substance by the members of the general assembly.
   This bill relates to direct acting antivirals, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission (commission).
   The bill prohibits the department of health and human services from requiring prior authorization for direct acting antiviral medications used to treat hepatitis C that are on the preferred drug list for the medical assistance program.
   The bill requires the commission to review, by July 1, 2026, the prescription drug vosevi for placement on the preferred drug list pursuant to 42 U.S.C. §1396r-8 as a preferred direct acting antiviral for treatment of hepatitis C.